Pendulum: The Pioneers of Live Akkermansia
Clinically-studied, keystone strains designed to transform health through the gut microbiome.*
Reimagine the health of your patients by targeting the gut microbiome
Using cutting-edge technology and microbiome science, Pendulum was the first company in the US to market live Akkermansia muciniphila. Akkermansia supports the synthesis of health-promoting postbioitics and strengthens gut barrier integrity.*
Pendulum’s Akkermansia-containing formulations have been clinically studied and published in the British Medical Journal. Improving gut barrier function and maintaining healthy blood sugar levels with Pendulum’s strains is a foundational way to help your patients find optimal health by harnessing the power of the gut microbiome.*
Pendulum is now the #1 GI Doctor recommended Akkermansia brand product.**
Featured Products
Join the 29,000+ practitioners recommending Pendulum products.^
How providers are using Pendulum’s GLP-1 Probiotic Pro in clinical practice
In survey of healthcare providers who use Pendulum’s GLP-1 Probiotic Pro:
- 97% of healthcare providers recommend as a way to manage food cravings+
- 78% Recommend as a strategy to help patients transition off of GLP-1 medications, specifically to help manage food cravings associated with this transition+
- 64% Recommend as a first line approach before prescribing a GLP-1 medication+
- 53% Recommend in combination with GLP-1 medications+
Get to know the products
Fullscript and Pendulum provider survey with Akkermansia 500 Pro
98% Will continue to recommend Akkermansia 500 Pro**
94% Would recommend Akkermansia 500 Pro to other health care providers**
Glucose control clinical efficacy
Pendulum conducted a double-blind, placebo-controlled nutrition study that demonstrated:
-
- Pendulum Glucose Control’s safety for its intended use
- Glucose control has a significant statistical and clinical impact on A1c and post-meal blood sugar spikes3
- -0.6 A1c reduction
- -32.5% post prandial glucose spike reduction
References
**Based on a IQVIA survey of gastroenterologists, 2025
^Based on sales data, 2022-2025
+Based on a survey conducted internally in 2024 of 64 healthcare providers